In ₹ Crore except Per Share Latest Annual	MAKERSL FY26	BPLPHARMA FY23	JENBURPH FY26	KPL FY24	Peer Average
Valuation — at last close
P/E	—	45.39×	—	—	45.39×
P/B	◆ 2.05×	5.78×	—	—	5.78× -64%
EV/EBITDA	156.70×	◆ 51.68×	—	—	51.68× +203%
Market Cap	₹112 Cr	₹1,105 Cr	—	—	₹1,105 Cr -90%
Growth
Revenue CAGR 3Y	5.77%	—	◆ 7.26%	—	7.26% -21%
Revenue CAGR 5Y	1.55%	—	◆ 9.07%	—	9.07% -83%
Net Income CAGR 3Y	—	—	12.18%	—	12.18%
Profitability
EBITDA Margin	1.45%	9.80%	◆ 23.81%	21.69%	18.43% -92%
Net Income Margin	-3.42%	11.16%	◆ 20.59%	—	15.88% -122%
Return on Common Equity	-3.11%	13.63%	◆ 18.84%	—	16.23% -119%
Return on Capital Employed	—	—	—	19.78%	19.78%
Return on Assets	-2.37%	9.25%	◆ 16.45%	—	12.85% -118%
Credit & Quality
Total Debt/Equity	0.05×	◆ 0.04×	—	0.43×	0.23× -79%
Interest Coverage	-3.91×	◆ 7.10×	—	4.54×	5.82× -167%
Scale — latest FY
Revenue / Total Income	₹50.3 Cr	₹218 Cr	₹169 Cr	₹307 Cr	₹231 Cr -78%
Net Income	−₹1.7 Cr	₹24.3 Cr	₹34.7 Cr	—	₹29.5 Cr -106%
Total Assets	₹73.5 Cr	₹308 Cr	₹226 Cr	₹398 Cr	₹311 Cr -76%
EPS	₹-2.91	₹42.14	—	—	₹42.14 -107%
Book Value per Share	₹92.11	₹330.83	—	—	₹330.83 -72%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.